These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24714525)

  • 21. Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.
    Lapouméroulie C; Benkerrou M; Odièvre MH; Ducrocq R; Brun M; Elion J
    Haematologica; 2005 Mar; 90(3):401-3. PubMed ID: 15749673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
    Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of fetal hemoglobin response to hydroxyurea.
    Steinberg MH
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea.
    Conran N; Fattori A; Saad ST; Costa FF
    Am J Hematol; 2004 Aug; 76(4):343-7. PubMed ID: 15282666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
    Madden NA; Jones GL; Kalpatthi R; Woods G
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):e382-6. PubMed ID: 24714503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Newborn Screening for Sickle Cell Disease: Indian Experience.
    Colah RB; Mehta P; Mukherjee MB
    Int J Neonatal Screen; 2018 Dec; 4(4):31. PubMed ID: 33072952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sickle Cell Disease: A Brief Update.
    Azar S; Wong TE
    Med Clin North Am; 2017 Mar; 101(2):375-393. PubMed ID: 28189177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients.
    Adekile AD
    Hemoglobin; 2011; 35(5-6):607-17. PubMed ID: 21999156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P; Barretto de Mello A; Figueiredo MS
    Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Sickle-cell disease: geographical distribution and population estimates].
    Piel FB
    Med Sci (Paris); 2013 Nov; 29(11):965-7. PubMed ID: 24280499
    [No Abstract]   [Full Text] [Related]  

  • 32. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
    Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin].
    de Montalembert M
    Pathol Biol (Paris); 1999 Jan; 47(1):55-8. PubMed ID: 10081780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perinatal outcome in sickle cell anemia: a prospective study from India.
    Daigavane MM; Jena RK; Kar TJ
    Hemoglobin; 2013; 37(6):507-15. PubMed ID: 23952263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HbSD-Punjab: clinical and hematological profile of a rare hemoglobinopathy.
    Oberoi S; Das R; Trehan A; Ahluwalia J; Bansal D; Malhotra P; Marwaha RK
    J Pediatr Hematol Oncol; 2014 Apr; 36(3):e140-4. PubMed ID: 24276032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strengthening Health System and Community Mobilization for Sickle Cell Disease Screening and Management among Tribal Populations in India: An Interventional Study.
    Babu BV; Sharma Y; Sridevi P; Surti SB; Bhat D; Ranjit M; Sudhakar G; Sarmah J
    Hemoglobin; 2023 Nov; 47(6):227-236. PubMed ID: 38189147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current perspectives of sickle cell disease in Nigeria: changing the narratives.
    Ojewunmi OO; Adeyemo TA; Ayinde OC; Iwalokun B; Adekile A
    Expert Rev Hematol; 2019 Aug; 12(8):609-620. PubMed ID: 31195888
    [No Abstract]   [Full Text] [Related]  

  • 40. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
    Patel DK; Mashon RS; Patel S; Das BS; Purohit P; Bishwal SC
    Hemoglobin; 2012; 36(5):409-20. PubMed ID: 22881992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.